Enanta Pharmaceuticals’ bid to treat low-risk respiratory syncytial virus (RSV) patients has gone off the rails. The failure of the phase 2b trial of N-protein inhibitor EDP-938 in the population sent Enanta’s stock to its lowest ebb since 2017 but failed to extinguish the biotech’s belief in the prospect in other settings.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,